We report a case of 55-year-old male with the diagnosis of malignant peritoneal mesothelioma (MPM). Initial evaluation with CT-scan and laparoscopy reveals unresectable peritoneal carcinomatosis with PCI at 39 with thickened omentum (star), small bowel (2 stars) and parietal peritoneum (dash-arrow) deposit, ascitis (plane-arrow) ([Figure 1](#j_pp-pp-2019-0011_fig_001){ref-type="fig"}A, B). Bidirectional chemotherapy (BDC) has been performed after three cycles of intravenous (IV) CISPLATIN -- PEMETREXED, with intensification combining three cycles of IV PEMETREXED with intraperitoneal (IP) CISPLATIN ([Figure 2](#j_pp-pp-2019-0011_fig_002){ref-type="fig"}). At reevaluation, PCI was still at 39 with a macroscopic response ([Figure 3](#j_pp-pp-2019-0011_fig_003){ref-type="fig"}A, B). The peritoneal disease was thinner allowing a complete CRS with DOXORUBICIN/CISPLATIN based-HIPEC.

BDC allowed selecting patients with initially unresectable MPM to undergo surgery and increase the overall survival (OS) \[[@j_pp-pp-2019-0011_ref_001], [@j_pp-pp-2019-0011_ref_002]\]. New IP delivery with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) reported promising results in palliative treatment of MMP \[[@j_pp-pp-2019-0011_ref_003]\] and is under evaluation to increase OS and secondary resectability of huge MMP (Clinical Trials NCT03875144).
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![CT scan (A) and laparoscopic evaluation (B) after bi--directional chemotherapy.](pp-pp-2019-0011_g003){#j_pp-pp-2019-0011_fig_003}
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